Tandem management at Goldman Sachs conference highlighted the FDA submission timeline for a next-gen algorithm as the key catalyst. Gross margins face pressure from the Mobi ramp, while international sales growth offers a partial offset.
Tandem Diabetes Care (TNDM) management appeared at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, just days after the American Diabetes Association (ADA) annual meeting. The timing let the company frame its next major catalyst: the submission of a next-generation automated insulin delivery (AID) algorithm to the FDA, expected in the third quarter of 2026.
At ADA, Tandem presented clinical data reinforcing the time-in-range and hypoglycemia reduction performance of its Control-IQ algorithm. The real question for doctors and payers is whether the next algorithm–designed to require less user intervention–can show a statistically meaningful advantage over the current Control-IQ and over competitor systems from Insulet (Omnipod 5) and Medtronic (MiniMed 780G). Management used the conference Q&A to signal that the algorithm development is on track and that it will be compatible with both the t:slim X2 and Mobi pump platforms.
Tandem’s revenue hit $820 million in fiscal 2025, up 8% year over year. Growth has decelerated from pandemic-era highs as the pump market becomes more crowded. Management guided for gross margins in the low 60% range for 2026, citing higher component costs and the learning curve on the Mobi pump line.
Mobi is Tandem’s answer to the patch-pump segment dominated by Insulet’s Omnipod 5. It features a 360-degree rotating cannula and full smartphone control–differentiators that appeal to active users who want a smaller, more discreet device. The margin pressure stems from low initial production volumes on Mobi. As volumes scale, Tandem expects to reach manufacturing efficiency similar to the t:slim X2 line. The risk is that Insulet’s installed base and brand loyalty make it harder for Tandem to win enough new users to hit those volume targets quickly.
International revenue is growing faster than the U.S. business, with management targeting 15% to 20% annual growth over the next three years. The Japanese market is a particular focus because of high diabetes prevalence and a reimbursement system that favors advanced AID technology. Tandem is building direct-to-consumer sales channels in Europe and Japan rather than relying solely on distributors, which gives it better control over customer acquisition cost and service margins.
If international growth hits that 15–20% range, it can partially offset the gross margin compression from Mobi’s initial ramp. If it falls short, the overall margin outlook becomes more dependent on domestic market share defense, which requires matching Insulet’s rebates and patient assistance programs. Tandem is maintaining list prices but offering more aggressive rebates–a strategy that protects volume at the expense of net revenue per pump.
The most concrete near-term pivot is the FDA submission for the next-generation algorithm, expected in Q3 2026. If the submission proceeds on schedule and the algorithm demonstrates superiority in clinical trial data, Tandem can regain momentum with prescribers and potentially expand its addressable market. Any regulatory setback would leave the company defending share with an aging algorithm against well-funded competitors who are also investing in next-generation systems.
For broader context on how medical device companies are navigating the current rate environment and sector rotation, see AlphaScala’s stock market analysis. The Tandem setup is a binary bet on algorithm execution and international scale–two factors that will determine whether the stock can justify a multiple that already prices in moderate growth.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.